닥플 플러스
KSMO 2026(3일차)
대한종양내과학회(17.5 명칭변경 한국임상암학회)
연수평점 :6점
오프라인
주관
대한종양내과학회(17.5 명칭변경 한국임상암학회)
교육일자
2026-09-04
수강료
300,000원
교육형태
오프라인
등록일시
2026-08-07
교육시간
26시간 50분
연수평점
6점
장소
서울특별시 그랜드 인터컨티넨탈 서울 파르나스(그랜드볼룸A,B, 오키드룸,매그놀리아룸, 로즈룸)
교육종류
내과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-09-04 | 08:30~08:52 | Emerging role of chemo-immunotherapy-based strategies in perioperative gastric and esophagogastric junction adenocarcinoma | Keiji Sugiyama(National Hospital Organization Nagoya Medical Center Japan) | - |
| 2026-09-04 | 08:52~09:14 | Perioperative therapy in MSI-H colorectal cancer | Ji Yoon Jung(Kyungpook National University Chilgok Hospital Korea) | - |
| 2026-09-04 | 09:14~09:36 | Perioperative systemic therapy in muscle-invasive bladder cancer: The rise of chemo-immunotherapy and antibody-drug conjugate combinations | Yoon Ji Choi(Korea University Anam Hospital Korea) | - |
| 2026-09-04 | 09:36~10:00 | Perioperative therapy in NSCLC | Junko Tanizaki(Kindai University Faculty of Medicine Japan) | - |
| 2026-09-04 | 10:00~10:20 | 휴식 | - | - |
| 2026-09-04 | 10:20~11:00 | ctDNA and minimal residual disease in colorectal cancer: Evidence, challenges and the road ahead | Jeanne Tie(Peter MacCallum Cancer Centre Australia) | - |
| 2026-09-04 | 11:00~11:20 | 휴식 | - | - |
| 2026-09-04 | 11:20~12:00 | Optimizing perioperative treatment with pembrolizumab in early TNBC (Tentative) | Changhee Park(Seoul National University Hospital Korea) | - |
| 2026-09-04 | 12:00~12:10 | 휴식 | - | - |
| 2026-09-04 | 12:10~12:32 | The AI-powered OR: Smarter robotic surgery for better oncologic outcomes | Jin Soo Rhu(Samsung Medical Center Korea) | - |
| 2026-09-04 | 12:32~12:54 | The digital health revolution in cancer care: The next wave in clinical oncology | Debra Patt(Texas Oncology The US Oncology Network USA) | - |
| 2026-09-04 | 12:54~13:16 | Closing the gap between AI model and clinical impact | Ravi B. Parikh(Emory University USA) | - |
| 2026-09-04 | 13:16~13:40 | Application of AI in the pathologic diagnosis of gastric cancer | Young Soo Park(Asan Medical Center Korea) | - |
| 2026-09-04 | 13:40~13:50 | 휴식 | - | - |
| 2026-09-04 | 13:50~14:30 | Encouraging results and updates on personalized cancer vaccines | Catherine Wu(Dana–Farber Cancer Institute USA) | - |
| 2026-09-04 | 14:30~14:40 | Discussion | - | - |
| 2026-09-04 | 14:40~15:02 | Early breast cancer guidelines | Giuseppe Curigliano(European Institute of Oncology IRCCS and Università degli Studi di Milano Italy) | - |
| 2026-09-04 | 15:02~15:24 | Metastatic breast cancer guidelines | Nadia Harbeck(LMU University Hospital Munich Germany) | - |
| 2026-09-04 | 15:24~15:46 | PAGA guideline and breast cancer management in Asia | Kyong Hwa Park(Korea University Anam Hospital Korea) | - |
| 2026-09-04 | 15:46~16:10 | Optimizing early breast cancer treatment outcome using biomarkers | Min Hwan Kim(Yonsei Cancer Center Korea) | - |
| 2026-09-04 | 16:10~16:30 | Closing Ceremony | - | - |
| 2026-09-04 | 08:30~08:45 | Pathway-centric AI for interpretable spatial transcriptomics | Sangsoo Lim(Dongguk University Korea) | - |
| 2026-09-04 | 08:45~09:00 | Translating digital pathology into spatial intelligence: AI-driven models for precision oncology | Kwon Joong Na(Seoul National University Hospital Korea) | - |
| 2026-09-04 | 09:00~09:30 | Pathology and spatial genomics | Ankur Sharma(Garvan Institute of Medical Research Australia) | - |
| 2026-09-04 | 09:30~10:00 | Opportunities for combinatorial precision oncology enabled by routine comprehensive molecular profiling | Marc Ladanyi(MSKCC USA) | - |
| 2026-09-04 | 10:00~10:20 | 휴식 | - | - |
| 2026-09-04 | 10:20~11:00 | ctDNA and minimal residual disease in colorectal cancer: Evidence, challenges and the road ahead(A룸 강연 동시송출) | Jeanne Tie(Peter MacCallum Cancer Centre Australia) | - |
| 2026-09-04 | 11:00~11:20 | - | - | - |
| 2026-09-04 | 11:20~12:00 | Zolbetuximab in metastatic gastric cancer: Clinical value and future role in the CLDN18.2-targeted therapy era | In-Ho Kim(The Catholic University of Korea Seoul St. Mary’s Hospital Korea) | - |
| 2026-09-04 | 12:00~12:10 | 휴식 | - | - |
| 2026-09-04 | 12:10~12:32 | CLDN18.2-targeted therapy: Scaling the momentum from gastric cancer to broader GI applications | Izuma Nakayama(National Cancer Center Hospital East Japan) | - |
| 2026-09-04 | 12:32~12:54 | FGFR targeting in GI cancers: Progress, challenge, future | Do-Youn Oh(Seoul National University Hospital Korea) | - |
| 2026-09-04 | 12:54~13:16 | Targeting the “undruggable”: Breakthroughs and the evolving landscape of RAS inhibition in GI cancers | Eejung Kim(Dana-Farber Cancer Institute USA) | - |
| 2026-09-04 | 13:16~13:40 | The next wave of HER2-targeted therapy: Strategic expansion across the GI landscape | James Harding(MSKCC USA) | - |
| 2026-09-04 | 13:40~13:50 | 휴식 | - | - |
| 2026-09-04 | 13:50~14:30 | Encouraging results and updates on personalized cancer vaccines(A룸 강연 동시송출) | Catherine Wu(Dana–Farber Cancer Institute USA) | - |
| 2026-09-04 | 14:30~14:40 | 휴식 | - | - |
| 2026-09-04 | 14:40~15:05 | The evolving treatment landscape for EGFR-Mutated locally advanced NSCLC | Sehhoon Park(Samsung Medical Center Korea) | - |
| 2026-09-04 | 15:05~15:30 | Choosing the best first-line strategy of EGFR mutant NSCLC: To combine or not to combine? | Stephen Liu(Georgetown University USA) | - |
| 2026-09-04 | 15:30~16:00 | Establishing ADCs as the new standard of care after 3rd Gen EGFR-TKI failure | Ross Soo(National University Hospital Singapore) | - |
| 2026-09-04 | 16:00~16:10 | 휴식 | - | - |
| 2026-09-04 | 08:30~08:52 | Deep learning frameworks for translating cancer drug response from cell-level to patient-level by modeling transcriptome | Sun Kim(Seoul National University Korea) | - |
| 2026-09-04 | 08:52~09:14 | Patient-Derived Organoids (PDOs) | Wonyoung Choi(National Cancer Center Korea) | - |
| 2026-09-04 | 09:14~09:36 | Functional genomics approach involving CRISPR-Cas9 screens for precision medicine | Tackhoon Kim(KIST Korea) | - |
| 2026-09-04 | 09:36~10:00 | Single-cell and spatial omics | Ji-Yeon Kim(Samsung Medical Center Korea) | - |
| 2026-09-04 | 10:00~10:20 | 휴식 | - | - |
| 2026-09-04 | 10:20~11:00 | ctDNA and minimal residual disease in colorectal cancer: Evidence, challenges and the road ahead(A룸 강연 동시송출) | Jeanne Tie(Peter MacCallum Cancer Centre Australia) | - |
| 2026-09-04 | 11:00~11:20 | 휴식 | - | - |
| 2026-09-04 | 11:20~12:00 | Early intervention with T-DXd in HER2-expressing mBC: Toward a new clinical paradigm | Ji-Yeon Kim(Samsung Medical Center Korea) | - |
| 2026-09-04 | 12:00~12:10 | 휴식 | - | - |
| 2026-09-04 | 12:10~12:35 | Current trends in esophageal cancer surgery in Japan and Asian countries | Koji Kono(Fukushima Medical University Japan) | - |
| 2026-09-04 | 12:35~13:00 | Neoadjuvant and perioperative treatment for esophageal cancer: Integrating immunotherapy into clinical practice in Asia | Feng Wang(Sun Yat-Sen University Cancer Center China) | - |
| 2026-09-04 | 13:00~13:30 | Toward precision care in esophageal cancer: Asian perspectives on biomarkers and future directions | Sook Ryun Park(Asan Medical Center Korea) | - |
| 2026-09-04 | 13:30~14:40 | 휴식 | - | - |
| 2026-09-04 | 14:40~15:05 | First-line treatment for advanced cholangiocarcinoma: Evolving standards in Asia | Masafumi Ikeda(National Cancer Center Hospital East Japan) | - |
| 2026-09-04 | 15:05~15:30 | Biomarker-driven therapy for cholangiocarcinoma: Emerging precision oncology in Asia | Haitao Zhao(Peking Union Medical College Hospital China) | - |
| 2026-09-04 | 15:30~16:00 | Future directions in cholangiocarcinoma: Building Asian collaboration for next-generation therapies | Jung Yong Hong(Samsung Medical Center Korea) | - |
| 2026-09-04 | 16:00~16:10 | 휴식 | - | - |
| 2026-09-04 | 08:30~08:55 | Neoadjuvant/adjuvant strategies in resectable NSCLC: Surgery, SBRT, or systemic therapy? | Jang Ho Cho(Gachon University Gil Medical Center Korea) | - |
| 2026-09-04 | 08:55~09:20 | Radiotherapy for oligoprogressive NSCLC (Oligometastatic lung cancer: Who benefits from local ablative therapy?) | Jae Myoung Noh(Samsung Medical Center Korea) | - |
| 2026-09-04 | 09:20~09:50 | Managing toxicity across disciplines: When treatment decisions collide | Hye Ryeon Kim(Dong-A University Hospital Korea) | - |
| 2026-09-04 | 09:50~10:20 | 휴식 | - | - |
| 2026-09-04 | 10:20~11:00 | ctDNA and minimal residual disease in colorectal cancer: Evidence, challenges and the road ahead(A룸 강연 동시송출) | Jeanne Tie(Peter MacCallum Cancer Centre Australia) | - |
| 2026-09-04 | 11:00~11:20 | 휴식 | - | - |
| 2026-09-04 | 11:20~12:00 | Lazertinib as a new standard for EGFRm+ NSCLC : Powerful as one, stronger as two | Jii Bum Lee(Yonsei Cancer Center Korea) | - |
| 2026-09-04 | 12:00~12:10 | 휴식 | - | - |
| 2026-09-04 | 12:10~12:32 | Clinical efficacy and safety management of T-cell engagers in solid tumors | Chang Gon Kim(Yonsei Cancer Center Korea) | - |
| 2026-09-04 | 12:32~12:54 | Personalized T-cell targeting in solid tumors: From neoantigen discovery to clinical translation | Derin B. Keskin(Dana-Farber Cancer Institute USA) | - |
| 2026-09-04 | 12:54~13:16 | Navigating the clinical landscape of TIL therapy | Yong Wha Moon(CHA University Bundang Medical Center Korea) | - |
| 2026-09-04 | 13:16~13:40 | Translational strategies to enhance immune cell therapy in solid cancers | Marco Donia(Copenhagen University Hospital Denmark) | - |
| 2026-09-04 | 13:40~13:50 | 휴식 | - | - |
| 2026-09-04 | 13:50~14:30 | Encouraging results and updates on personalized cancer vaccines(A룸 강연 동시송출) | Catherine Wu(Dana–Farber Cancer Institute USA) | - |
| 2026-09-04 | 14:30~14:40 | 휴식 | - | - |
| 2026-09-04 | 14:40~14:50 | (ORAL)Coordinated SIRPα-PD-L1-TGFβ modulation with HCB301: Early safety and disease control in a first-in-human phase 1 study | Ji Zhu(Zhejiang Cancer Hospital China) | - |
| 2026-09-04 | 14:50~15:00 | (ORAL)Molecular tumor board–guided precision oncology trial in pretreated metastatic solid tumors: Results of the KOSMOS-II; a prospective nationwide master observational study (KCSG AL-22-09) | Sun Young Kim(Asan Medical Center Korea) | - |
| 2026-09-04 | 15:00~15:10 | (ORAL)Radiotherapy-induced in situ vaccination combined with Chidamide and PD-1 antibody for advanced soft tissue sarcoma: An exploratory, single-center, single-arm trial | Xiaolu Wang(Nanjing Drum Tower Hospital China) | - |
| 2026-09-04 | 15:10~15:20 | (ORAL)Clinical outcomes and radiogenomic features of lenvatinib benefit in advanced biliary tract cancer | Sunyoung Lee(MD Anderson Cancer Center USA) | - |
| 2026-09-04 | 15:20~15:30 | (ORAL)Phase ib study of belvarafenib in combination with cobimetinib in advanced solid tumors: Clinical activity in NRAS-mutant melanoma supporting further development | Minsuk Kwon(Samsung Medical Center Korea) | - |
| 2026-09-04 | 15:30~15:40 | (ORAL)Nk cells potentiate atezolizumab/bevacizumab efficacy in hepatocellular carcinoma by remodeling the tumor microenvironment | Hyeon-Jong Kim(Chonnam National University Hwasun Hospital Korea) | - |
| 2026-09-04 | 15:40~16:10 | Oral Discussion | - | - |
| 2026-09-04 | 08:30~09:10 | Redefining patient outcomes from 1L to post-progression: The strategic role of rybrevant | Seo Young Lee(Gangnam Severance Hospital Korea) | - |
| 2026-09-04 | 09:10~09:50 | FTD/TPI based treatment for mCRC: From evidence to clinical practice | Ji Eun Shin(Samsung Medical Center Korea) | - |
| 2026-09-04 | 09:50~10:20 | 휴식 | - | - |
| 2026-09-04 | 10:20~11:00 | ctDNA and minimal residual disease in colorectal cancer: Evidence, challenges and the road ahead(A룸 강연 동시송출) | Jeanne Tie(Peter MacCallum Cancer Centre Australia) | - |
| 2026-09-04 | 11:00~11:20 | 휴식 | - | - |
| 2026-09-04 | 11:20~12:10 | 점심 | - | - |
| 2026-09-04 | 12:10~12:50 | Perioperative strategies in MIBC: Advancing toward a new standard of care | Jungmin Jo(Ehwa Womans University Mokdong Hospital Korea) | - |
| 2026-09-04 | 12:50~13:30 | VISION in practice: Real‑world performance of PSMA RLT | Eun Hee Jung(Seoul National University Bundang Hospital Korea) | - |
| 2026-09-04 | 13:30~13:50 | 휴식 | - | - |
| 2026-09-04 | 13:50~14:30 | Encouraging results and updates on personalized cancer vaccines(A룸 강연 동시송출) | Catherine Wu(Dana–Farber Cancer Institute USA) | - |
| 2026-09-04 | 14:30~14:40 | 휴식 | - | - |
| 2026-09-04 | 14:40~15:20 | Recent advances with Fruquintinib in mCRC: Clinical evidence and case-based insights | Kentaro Yamazaki(Shizuoka Cancer Center Japan) | - |
| 2026-09-04 | 15:20~16:10 | 휴식 | - | - |
비고
구분 즉시등록(5월 15일까지) 사전등록(7월 31일까지) 일반등록(8월 1일부터)교수/전문의(학교 및 병원) 회원 150,000원 200,000원 250,000원비회원 170,000원 230,000원 300,000원전임의/간호사/약사/군관 50,000원 60,000원 80,000원업체 및 기타 170,000원 230,000원 300,000원전공의/학생/대학생 무료
문의처
담당자
김예지
연락처
02-735-2857
이메일
meetings@ksmo.or.kr